Table 1. Association between EpCAM expression pattern and clinicopathological features in patients with ovarian cancer.
| Patient characteristic | Total (n = 168) | EpCAM | P value | |
|---|---|---|---|---|
| high (n = 97) | low (n = 71) | |||
| Median age (range) | 55.0 (22–87) | 55.0 (27–87) | 51.0 (22–79) | 0.331 |
| Menopause status | ||||
| pre | 57 (33.9%) | 29 (29.9%) | 28 (39.4%) | 0.197 |
| post | 111 (66.1%) | 68 (70.1%) | 43 (60.6%) | |
| Median BMI (range) | 22.2 (15.3–32.7) | 22.4 (15.9–32.4) | 21.9 (15.3–32.7) | 0.385 |
| Histological type | ||||
| serous | 75 (44.6%) | 43 (44.3%) | 32 (45.1%) | 0.111 |
| clear cell | 23 (13.7%) | 9 (9.3%) | 14 (19.7%) | |
| endometrioid | 28 (16.7%) | 17 (17.5%) | 11 (15.5%) | |
| mucinous | 20 (11.9%) | 16 (16.5%) | 4 (5.6%) | |
| other | 22 (13.1%) | 12 (12.4%) | 10 (14.1%) | |
| FIGO stage | ||||
| I | 63 (37.5%) | 32 (33.0%) | 31 (43.7%) | 0.446 |
| II | 17 (10.1%) | 12 (12.4%) | 5 (7.0%) | |
| III | 59 (35.1%) | 36 (37.1%) | 23 (32.4%) | |
| IV | 29 (17.3%) | 17 (17.5%) | 12 (16.9%) | |
| CA125 | ||||
| < 500 U/mls | 87 (51.8%) | 48 (49.5%) | 38 (53.5%) | 0.700 |
| ≥ 500 U/ml | 81 (48.2%) | 49 (50.5%) | 33 (46.5%) | |
| Tumor size | ||||
| < 10 cm | 77 (45.8%) | 46 (47.4%) | 31 (43.7%) | 0.629 |
| ≥ 10 cm | 91 (54.2%) | 51 (52.6%) | 40 (56.3%) | |
| Residual tumor size | ||||
| 0 mm (complete surgery) | 112 (66.7%) | 63 (65.0%) | 49 (69.0%) | 0.127 |
| 1–10 mm (optimal surgery) | 17 (10.1%) | 7 (7.2%) | 10 (14.1%) | |
| > 10 mm (suboptimal surgery) | 39 (23.2%) | 27 (27.8%) | 12 (16.9%) | |
| First-line chemotherapy | ||||
| Platinum based chemotherapy | 144 (85.7%) | 83 (85.6%) | 61 (85.9%) | 0.688 |
| Other regimen | 1 (0.6%) | 1 (1.0%) | 0 (0.0%) | |
| No adjuvant therapy | 23 (13.7%) | 13 (13.4%) | 10 (14.1%) | |
| No. of cycles of chemotherapy | ||||
| < 2 | 137 (81.5%) | 77 (79.4%) | 60 (84.5%) | 0.398 |
| ≥ 3 | 31 (18.5%) | 20 (20.6%) | 11 (15.5%) | |